An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: Use in differentiation of ovarian cancers and benign lesions

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1811-1817

  Macuks, Ronalds ^a   Baidekalna, Ieva ^a   Donina, Simona ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

Cancer antigen; Human epididymis secretory protein 4; Ovarian cancer

Indexed keywords

APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PREALBUMIN; TRANSFERRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; OVARY TUMOR; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84868160162     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0440-1     Document Type: Article

References (14)

1. Abraham J. OVA1 test for preoperative assessment of ovarian cancer. Community Oncol. 2010;7:249-50.
2. Heintz AP, Odicino F, Maisonneuve P, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. Int J Gynaecol Obstetetrics. 2006;95:161-S192.
3. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian cancer. Cancer Res. 2003;63:3695-700.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
6. Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012;22(2):238-44.
7. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;17:4589-96.
8. Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, Anastasi E. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biol. 2012. [Epub ahead of print].
9. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32(6):1087-95.
10. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast Jr RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206(4):351.e1-8. Epub 2011 Dec 30.
11. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast Jr RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6.
12. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecology. 2009;200(6):639.e1-5.
13. Shapiro S, Wilk M. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591-611.
14. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448-52.